Streetbeat News

Analyst Ratings

AKBA

HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) and increased the price target from $3.75 to $5. This adjustment suggests a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:10 pm

PENN

Needham analyst Bernie McTernan has reiterated a Buy rating on PENN Entertainment (NASDAQ:PENN) and maintained a $33 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 12:03 pm

ABNB

Over the last quarter, Airbnb (NASDAQ:ABNB) received 10 analyst ratings with an average 12-month price target of $136.8, a decrease of 2.11% from the previous target of $139.75. The ratings include 2 bullish, 1 somewhat bullish, 6 indifferent, 1 somewhat bearish, and 0 bearish. Analysts rate stocks typically once per quarter and provide insights such as earnings, revenue, and growth estimates.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:00 pm

ASO

Over the past 3 months, 11 Wall Street analysts have provided ratings for Academy Sports (NASDAQ:ASO) stock, with an average price target of $64.36, representing an upside from the current price of $48.72. The consensus among these analysts is more bullish, with 3 bullish, 6 somewhat bullish, and 2 indifferent ratings. The average price target has increased by 1.51% from the previous target of $63.40. Analysts' ratings are based on research of financial statements, company meetings, and insider information, and are updated quarterly.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:00 pm

KVUE

Kenvue (NYSE:KVUE) has received mostly bullish analyst ratings in the last quarter, with 4 bullish, 1 somewhat bullish, and 1 indifferent rating. The average 12-month price target among 6 analysts is $26.00, with a high of $29.00 and a low of $20.00. This target has decreased by 10.34% from the previous target of $29.00. Analysts' ratings are based on information from company calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:00 pm

IONS

Over the past 3 months, 8 Wall Street analysts have published their opinions on Ionis Pharmaceuticals (NASDAQ:IONS), with an average price target of $52.62, representing an implied upside from the current price of $48.54. The ratings include 3 bullish, 1 somewhat bullish, 3 indifferent, and 1 bearish. The average price target has increased by 45.16% over the past month. Analysts typically review stocks quarterly or after major company updates, basing their predictions on financial analysis and company performance.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:00 pm

NKE

Over the past 3 months, 22 Wall Street analysts have provided ratings for Nike (NYSE:NKE), with an average price target of $119.55, which is an implied upside from the current price of $108.5. The consensus includes 4 bullish, 13 somewhat bullish, 4 indifferent, and 1 bearish rating. The current average price target has decreased by 4.58% from the previous target of $125.29. Analysts typically review stocks quarterly or after major company updates, considering factors like earnings, revenue, and growth estimates.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:00 pm

BBWI

Over the past 3 months, 7 Wall Street analysts have published their ratings on Bath & Body Works (NYSE:BBWI), with 4 somewhat bullish, 2 indifferent, and 1 somewhat bearish. The average 12-month price target is $40.29, a decrease from the previous $45.75. Ratings are used to predict stock performance and are updated quarterly.

Portfolio Pulse from Benzinga Insights

November 17, 2023 | 12:00 pm

CHPT

Needham analyst Chris Pierce maintains a Buy rating on ChargePoint Holdings (CHPT) but reduces the price target from $8 to $4.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:52 am

GLOB

Needham analyst Mayank Tandon has reaffirmed a Buy rating on Globant (NYSE:GLOB) and increased the price target from $205 to $215.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 11:51 am